caffeine + codeine + paracetamol: clinical use

Prescribing considerations

• Confirm that acute moderate pain has not been adequately relieved by suitable non-opioid analgesia.
• Review total paracetamol, codeine, opioid, sedative and caffeine exposure from every source.
• Assess respiratory disease, hepatic or renal impairment, alcohol use, constipation, frailty and susceptibility to sedation.
• Assess personal or family history of substance-use disorder and current mental-health or tobacco-use risk factors.
• Explain opioid toxicity, dependence, withdrawal and medication-overuse headache.

Contraindications and cautions

• Hypersensitivity to any active ingredient or relevant excipient.
• Known CYP2D6 ultra-rapid metabolism.
• Respiratory depression; the selected capsule also lists chronic constipation and raised intracranial pressure.
• Severe liver disease for the selected capsule product.
• Breastfeeding and product-specific pregnancy restrictions.
• Children younger than 12 years, and patients younger than 18 years following tonsillectomy or adenoidectomy for obstructive sleep apnoea.

Monitoring

• Analgesic response and continued need.
• Sedation, respiratory rate and signs of morphine toxicity, especially with respiratory compromise or interacting sedatives.
• Constipation, urinary retention and other opioid adverse effects.
• Escalating use, craving, withdrawal, hyperalgesia or medication-overuse headache.
• Liver-risk factors and cumulative paracetamol exposure; consider anticoagulation monitoring when clinically relevant.

Clinical pharmacology

Paracetamol provides central analgesic and antipyretic activity. Codeine is a weak opioid prodrug whose conversion to morphine through CYP2D6 produces variable analgesia and toxicity. Caffeine is rapidly absorbed, enters the central nervous system and acts as a stimulant and analgesic adjuvant.

Formulation and product differences

• The selected hard capsule contains gelatin and Ponceau 4R, which may cause allergic reactions; it is essentially sodium-free.
• The soluble formulation must be dissolved in water and contains substantial sodium plus sorbitol, relevant to sodium restriction and hereditary fructose intolerance.
• Formulations are not interchangeable without checking their active ingredients, excipients and instructions.